Insmed Incorporated (NASDAQ:INSM) Receives $45.10 Consensus PT from Brokerages

Insmed Incorporated (NASDAQ:INSM) has received an average rating of “Buy” from the ten brokerages that are currently covering the firm, Marketbeat.com reports. Ten analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have covered the stock in the last year is $45.10.

Several brokerages recently weighed in on INSM. Guggenheim raised their price target on shares of Insmed from $52.00 to $54.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $55.00 price target on shares of Insmed in a research report on Monday, April 1st. UBS Group began coverage on shares of Insmed in a research report on Tuesday, February 27th. They set a “buy” rating and a $46.00 target price on the stock. StockNews.com raised shares of Insmed from a “sell” rating to a “hold” rating in a research report on Wednesday, February 28th. Finally, Wolfe Research began coverage on shares of Insmed in a research report on Thursday, February 15th. They set an “outperform” rating and a $42.00 target price on the stock.

Insmed Price Performance

Shares of INSM opened at $28.01 on Friday. The stock has a 50-day moving average of $27.68 and a 200-day moving average of $26.98. The company has a market cap of $4.16 billion, a PE ratio of -5.25 and a beta of 0.92. Insmed has a one year low of $16.46 and a one year high of $32.00.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, missing the consensus estimate of ($1.13) by ($0.15). The company had revenue of $83.70 million for the quarter, compared to analyst estimates of $82.15 million. During the same quarter last year, the firm posted ($1.20) earnings per share. The business’s quarterly revenue was up 41.1% compared to the same quarter last year. Analysts expect that Insmed will post -4.65 EPS for the current fiscal year.

Insider Activity

In other news, COO Roger Adsett sold 5,251 shares of Insmed stock in a transaction on Friday, January 12th. The shares were sold at an average price of $28.63, for a total transaction of $150,336.13. Following the completion of the sale, the chief operating officer now directly owns 148,559 shares of the company’s stock, valued at approximately $4,253,244.17. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, COO Roger Adsett sold 5,251 shares of Insmed stock in a transaction on Friday, January 12th. The shares were sold at an average price of $28.63, for a total transaction of $150,336.13. Following the completion of the sale, the chief operating officer now directly owns 148,559 shares of the company’s stock, valued at approximately $4,253,244.17. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Martina M.D. Flammer sold 4,667 shares of Insmed stock in a transaction on Friday, January 12th. The stock was sold at an average price of $28.63, for a total transaction of $133,616.21. Following the sale, the insider now directly owns 106,898 shares of the company’s stock, valued at $3,060,489.74. The disclosure for this sale can be found here. Company insiders own 4.30% of the company’s stock.

Institutional Trading of Insmed

Several hedge funds have recently added to or reduced their stakes in INSM. International Assets Investment Management LLC bought a new stake in Insmed in the fourth quarter worth $25,000. Almanack Investment Partners LLC. bought a new stake in Insmed in the third quarter worth $25,000. State of Wyoming bought a new stake in Insmed in the fourth quarter worth $31,000. Quantbot Technologies LP lifted its stake in Insmed by 2,170.4% in the second quarter. Quantbot Technologies LP now owns 2,452 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 2,344 shares during the last quarter. Finally, RVW Wealth LLC bought a new position in shares of Insmed during the third quarter valued at about $53,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.